페니트리움바이오

187660KOSDAQ자연과학 및 공학 연구개발업

53.5 / 100

Reference Date: 2026-06-10

Financial Score14.0 / 40

News Sentiment19.5 / 25

Momentum8.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Plunged 32.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Penitrium Bio operates as a Contract Research Organization (CRO), providing comprehensive clinical trial services to pharmaceutical companies and biotech ventures, leveraging AI and big data for digital clinical trial technologies. The company also conducts Phase IV clinical trials to monitor drug safety and efficacy post-market approval and develops oncology treatments through its biotech business.

Number of Employees

110people

Average Salary

72.6M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

17.11Industry Average 3.240.0Point

5.3x industry avg (risky)

ROE

-105.34Industry Average -32.093.5Point

3.3x industry avg (excellent)

Debt Ratio

3.59Industry Average 7.316.5Point

Half of industry avg (excellent)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼17.1% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼153.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -79.0% (declining, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 78

Positive
아이작스 "류머티즘 관절염 새 해법 제시할 것"
페니트리움바이오의 신약 개발 소식으로 류머티즘 관절염 치료 분야에서 혁신적인 진전이 기대됩니다.
Positive
페니트리움바이오, 네이처 논문 ‘수치’로 입증한 항암 내성 돌파구...
페니트리움바이오의 연구 결과가 네이처 커뮤니케이션즈에 게재되어 항암 내성 극복에 대한 중요한 진전을 보여주며 긍정적인 시장 반응을 예상합니다.
Positive
페니트리움바이오, 고형암 병용 1상 IND 변경신청..."글로벌 표준 ...
페니트리움바이오의 고형암 병용 임상 전략 변경으로 글로벌 시장 진출 기대감 증가.

Detailed Momentum

52-week position3.0Point

52w lower range (31%)

Current 6,640Won52-week high 18,67052-week low 1,135

1-month return0.0Point

1m -32.04% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 1Neutral 4Negative 0

Neutral[기재정정]증권신고서(지분증권)2026-05-27
Positive[기재정정]주요사항보고서(유상증자결정)2026-05-27
Neutral정정신고서제출요구( 2026.04.30. 제출 증권신고서(지분증권) )2026-05-18
Neutral분기보고서 (2026.03)2026-05-15
Neutral투자판단관련주요경영사항(임상시험계획변경승인신청) ((불응성/재발성 고형암 대상 펨브롤리주맙과 PenetriumTM 병용요법 1상 임상시험계획 변경승인 신청))2026-05-13